Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG

Jacques Wils, Tarek Sahmoud, Alberto Sobrero, Harry Bleiberg, Sam Ahmedzai, Jane Blazeby, Geert Blijham, Thierry Conroy, David Cunningham, Desmond Curran, Eduardo Díaz-Rubio, Michel Ducreux, Jeff Evans, Bengt Glimelius, Gillian Hutchinson, David Kerr, Gwendoline Kiebert, Hennig Köhne, Roberto Labianca, Rina LangendijkDonato Nitti, Bernard Nordlinger, Philippe Rougier, Werner Scheithauer, Hans Joachim Schmoll, Eric Van Cutsem, Theo Wagener, Jochen Wilke, Ann Marinus, Patrick Therasse

Research output: Contribution to journalArticlepeer-review

Abstract

During the last few years several factors have contributed to an increasing change in the medical treatment of advanced colorectal cancer. Among them are the more general acceptance of the impact of chemotherapy on quality of life and survival in first as well as in second-line treatment, the introduction of new drugs and the definition of novel endpoints which can roughly be defined as 'patient benefit'. For this reason the European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Cooperative Group (GITCCG) felt it was appropriate to organize a workshop with experts from different countries and national groups to discuss in depth several aspects concerning the treatment of patients with advanced colorectal cancer.

Original languageEnglish
Pages (from-to)335-347
Number of pages13
JournalTumori
Volume84
Issue number3
Publication statusPublished - May 1998

Keywords

  • Advanced colorectal cancer
  • Endpoints of medical treatment

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG'. Together they form a unique fingerprint.

Cite this